Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT00525668

Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study) (SuniMS)

Sunphenon EGCg (Epigallocatechin-gallate) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)

Sponsor: Charite University, Berlin, Germany

Conditions Relapsing-remitting Multiple Sclerosis

Interventions epigallocatechin-gallate (Sunphenon) placebo

Updated 7 times since 2017 Last updated: Jul 28, 2021 Started: Sep 30, 2007 Primary completion: Nov 30, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00525668, this PHASE1/PHASE2 trial focuses on Relapsing-remitting Multiple Sclerosis and remains completed. Sponsored by Charite University, Berlin, Germany, it has been updated 7 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Sep 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Sep 2021 [monthly]

Completed PHASE1_PHASE2
May 2020 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 2 earlier versions

Jun 2018 — May 2020 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Charite University, Berlin, Germany

Data source: Charite University, Berlin, Germany

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany